X

Drug Profile

CD38 GEAR NK cell anti-CD38 mAb companion diagnostic - Coeptis Therapeutics

Latest Information Update: 03 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Coeptis Therapeutics
Class Diagnostic agents
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Cancer

Most Recent Events

01 Aug 2023 Coeptis Therapeutics submits 513(g) request to the US FDA for CD38 GEAR NK cell anti-CD38 mAb companion diagnostic
29 Mar 2023 Coeptis Therapeutics exercises its option to acquire CD38-GEAR-NK cell therapy and CD38 diagnostic test from VyGen-Bio
29 Mar 2023 Early research in Cancer (Diagnosis) in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com